ALUMINUM TOXICITY

Course overview

ALUMINUM TOXICITY WAS PREVIOUSLY COMMON IN DIALYSIS PATIENTS DUE TO ELEVATED LEVELS IN DIALYSATE, BUT IT HAS BECOME RARE WITH IMPROVEMENTS IN THE DIALYSATE COMPOSITION. PATIENTS WITH END-STAGE RENAL DISEASE ARE PARTICULARLY SUSCEPTIBLE, AS ALUMINUM RELIES ON RENAL CLEARANCE AND WAS HISTORICALLY PRESENT IN SOME PHOSPHATE BINDERS. ALUMINUM EXPOSURE OCCURS THROUGH COSMETICS, FOOD PACKAGING, MEDICATIONS, WATER, AND INDUSTRIAL SOURCES. ALTHOUGH IT WAS INITIALLY BELIEVED TO PRIMARILY AFFECT THE NERVOUS SYSTEM AND BONES, ALUMINUM TOXICITY IS NOW KNOWN TO IMPACT THE CARDIAC, PULMONARY, REPRODUCTIVE, GASTROINTESTINAL, AND HEMATOLOGICAL SYSTEMS. SYMPTOMS INCLUDE ANEMIA, PULMONARY FIBROSIS, AND DECREASED BONE DENSITY.DIAGNOSIS OF THIS CONDITION INVOLVES MEASURING ALUMINUM LEVELS IN BIOLOGICAL SPECIMENS USING VARIOUS ADVANCED TECHNIQUES. TREATMENT FOCUSES ON CHELATION THERAPY WITH DEFEROXAMINE, WHICH BINDS ALUMINUM FOR EXCRETION, OFTEN REQUIRING DIALYSIS IN PATIENTS WITH RENAL INSUFFICIENCY. OTHER CHELATORS EXIST, BUT DEFEROXAMINE REMAINS THE MOST EFFECTIVE. EARLY RECOGNITION, INTERVENTION, AND PREVENTION HAVE TRANSFORMED ALUMINUM POISONING INTO A MANAGEABLE CONDITION WITH A FAVORABLE PROGNOSIS. THIS ACTIVITY EXPLORES THE CURRENT SCIENTIFIC UNDERSTANDING OF ALUMINUM POISONING, COVERING EXPOSURE SOURCES, AT-RISK POPULATIONS, ORGAN-SPECIFIC TOXICOLOGY, TREATMENT, AND PREVENTION TO PROVIDE HEALTHCARE PROFESSIONALS WITH THE ABILITY TO MANAGE ALUMINUM TOXICITY.